CA2295040A1 - Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo - Google Patents

Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo Download PDF

Info

Publication number
CA2295040A1
CA2295040A1 CA002295040A CA2295040A CA2295040A1 CA 2295040 A1 CA2295040 A1 CA 2295040A1 CA 002295040 A CA002295040 A CA 002295040A CA 2295040 A CA2295040 A CA 2295040A CA 2295040 A1 CA2295040 A1 CA 2295040A1
Authority
CA
Canada
Prior art keywords
dna
vivo
expression
coated stent
recombinant genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002295040A
Other languages
French (fr)
Other versions
CA2295040C (en
Inventor
Elizabeth G. Nabel
Gary J. Nabel
Zhi-Yong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
The Regents Of The University Of Michigan
Elizabeth G. Nabel
Gary J. Nabel
Zhi-Yong Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Elizabeth G. Nabel, Gary J. Nabel, Zhi-Yong Yang filed Critical The Regents Of The University Of Michigan
Publication of CA2295040A1 publication Critical patent/CA2295040A1/en
Application granted granted Critical
Publication of CA2295040C publication Critical patent/CA2295040C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings

Abstract

The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.
CA002295040A 1997-06-27 1998-06-26 Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo Expired - Fee Related CA2295040C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/884,352 1997-06-27
US08/884,352 US6818016B1 (en) 1997-06-27 1997-06-27 Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo
PCT/US1998/013301 WO1999000071A1 (en) 1997-06-27 1998-06-26 Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo

Publications (2)

Publication Number Publication Date
CA2295040A1 true CA2295040A1 (en) 1999-01-07
CA2295040C CA2295040C (en) 2005-08-23

Family

ID=25384436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295040A Expired - Fee Related CA2295040C (en) 1997-06-27 1998-06-26 Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo

Country Status (8)

Country Link
US (3) US6818016B1 (en)
EP (1) EP1023005B1 (en)
JP (2) JP2002507136A (en)
AT (1) ATE438361T1 (en)
AU (1) AU8267698A (en)
CA (1) CA2295040C (en)
DE (1) DE69841041D1 (en)
WO (1) WO1999000071A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
DE60122121T2 (en) * 2000-04-04 2007-03-08 Boston Scientific Ltd., Bush Hill MEDICAL DEVICES FOR GENE THERAPY PROCEDURES
US6812217B2 (en) * 2000-12-04 2004-11-02 Medtronic, Inc. Medical device and methods of use
US8038708B2 (en) * 2001-02-05 2011-10-18 Cook Medical Technologies Llc Implantable device with remodelable material and covering material
DE60106962T2 (en) 2001-12-12 2005-04-28 Hehrlein, Christoph, Dr. Porous metallic stent with a coating
US7491234B2 (en) 2002-12-03 2009-02-17 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents
EP1444995A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents
DE10311729A1 (en) * 2003-03-18 2004-09-30 Schultheiss, Heinz-Peter, Prof. Dr. Endovascular implant with an at least sectionally active coating of ratjadon and / or a ratjadon derivative
WO2004100836A1 (en) * 2003-05-12 2004-11-25 Cook Incorporated Stent graft
WO2007016251A2 (en) * 2005-07-28 2007-02-08 Cook Incorporated Implantable thromboresistant valve
US20070196423A1 (en) * 2005-11-21 2007-08-23 Med Institute, Inc. Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
CN100358483C (en) * 2005-12-28 2008-01-02 中国医学科学院生物医学工程研究所 Implanting device carried with plasmid DNA nanometer particle and its prepn. method
US8642063B2 (en) * 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US9587249B2 (en) 2008-10-27 2017-03-07 Baxalta GmbH Models of thrombotic thrombocytopenic purpura and methods of use thereof
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN104825249B (en) * 2015-04-28 2017-11-07 温州医科大学 A kind of surface mediated gene therapeutic type intraocular lens and preparation method thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5439446A (en) * 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5190540A (en) 1990-06-08 1993-03-02 Cardiovascular & Interventional Research Consultants, Inc. Thermal balloon angioplasty
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993006792A1 (en) 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5464450A (en) 1991-10-04 1995-11-07 Scimed Lifesystems Inc. Biodegradable drug delivery vascular stent
US5500013A (en) 1991-10-04 1996-03-19 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
US5336615A (en) * 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
US5571166A (en) * 1992-03-19 1996-11-05 Medtronic, Inc. Method of making an intraluminal stent
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
AU7019494A (en) 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6780406B1 (en) 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
US5588962A (en) * 1994-03-29 1996-12-31 Boston Scientific Corporation Drug treatment of diseased sites deep within the body
EP0754054B1 (en) * 1994-04-08 2002-07-03 Viron Therapeutics, Inc. Antirestenosis protein
AU6905696A (en) * 1995-09-01 1997-03-27 Emory University Endovascular support device and method of use
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6090618A (en) * 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.

Also Published As

Publication number Publication date
EP1023005B1 (en) 2009-08-05
US6818016B1 (en) 2004-11-16
US20080112997A1 (en) 2008-05-15
AU8267698A (en) 1999-01-19
US20050038499A1 (en) 2005-02-17
ATE438361T1 (en) 2009-08-15
CA2295040C (en) 2005-08-23
JP2002507136A (en) 2002-03-05
EP1023005A4 (en) 2006-06-14
WO1999000071A1 (en) 1999-01-07
EP1023005A1 (en) 2000-08-02
DE69841041D1 (en) 2009-09-17
JP2007301402A (en) 2007-11-22

Similar Documents

Publication Publication Date Title
CA2295040A1 (en) Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo
WO1999016416A3 (en) Coated medical implants, method for producing them, and use of the same for preventing restenosis
AU1724099A (en) Vascular stent for reduction of restenosis
IL161335A0 (en) Coating of stents for preventing restenosis
WO2003009779A3 (en) Delivery of therapeutic capable agents
CA2257976A1 (en) Compositions and methods for coating medical devices
FR2762777B1 (en) VASCULAR AND CORONARY EXTENDERS, USUALLY DESIGNATED UNDER THE NAME OF "STENT"
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
CA2290481A1 (en) Peptide-coated implants and processes for their preparation
EP1181903A3 (en) A stent for angioplasty and associated production process
AU7323396A (en) Braided stent
WO2003047651A3 (en) Apparatus and methods for delivery of multiple distributed stents
CA2308177A1 (en) Intravascular stent and method for manufacturing an intravascular stent
WO2002074194A3 (en) Stent with medicated multi-layer hydrid polymer coating
NO20012017L (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
AU8676898A (en) Endovascular coronary sinus catheter and method of use
WO2002087472A8 (en) Stent-based delivery of statins to prevent restenosis
WO2003059192A3 (en) C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
WO1997010334A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
WO1996021015A3 (en) Combination gene delivery vehicles
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
FR2786685B1 (en) VASCULAR AND CORONARY EXTENDERS, USUALLY DESIGNATED UNDER THE NAME OF "STENT"
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
DE59403687D1 (en) Process for the production of water-based pyrotechnic active compositions containing metal powder, coated metal powder and their use

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed